SEC Form 4 · accession 0001209191-15-053996
Receptos, Inc. · RCPT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
S. Edward Torres
Director
Period of report
Jun 12, 2015
Accepted (ET)
Jun 16, 2015 · 8:00 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001463729
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Jun 12, 2015 | S | 81,200 | $180.33 | D | 804,361 | I | See footnote |
| Common StockF3,F2 | Jun 15, 2015 | S | 88,400 | $175.54 | D | 715,961 | I | See footnote |
| Common StockF4,F2 | Jun 16, 2015 | S | 50,400 | $182.89 | D | 665,561 | I | See footnote |
| Common StockF5 | holding | — | — | — | 7,400 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $178.05 to $182.18 per share, inclusive. The reporting person undertakes to provide to Receptos, Inc., any security holder of Receptos, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes (1), (3) and (4).
- F2These shares are owned directly by Lilly Ventures Fund I, LLC (the "Fund"). Eli Lilly and Company, as sole Managing Member of the Fund, and pursuant to provisions of the LLC Agreement of the Fund, has voting authority with respect to shares owned by the Fund. S. Edward Torres is a non-managing member of the Fund and may be deemed to beneficially own the shares. Mr. Torres disclaims beneficial ownership of the shares held of record by the Fund, except to the extent of his pecuniary interest therein.
- F3The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $175.00 to $177.49 per share, inclusive.
- F4The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $175.00 to $188.28 per share, inclusive.
- F5Represents time-based restricted stock units which vest 100% on the first anniversary of the 5-28-15 date of grant.